Independent rankings of every major US tirzepatide telehealth provider — based on price, provider quality, shipping, transparency, and verified user experience. MEDVi takes the 2026 top spot.
We evaluated each provider on six criteria:
We do not publish provider rankings as paid placements. We do earn affiliate revenue from many providers we rank, including our top picks — see our affiliate disclosure. Rankings are based on the criteria above, not commission rates.
MEDVi has been our top pick since 2024 and remains so in 2026 for one main reason: it consistently delivers the lowest published self-pay tirzepatide price from a legitimate US-licensed provider network. The next-cheapest legitimate option (Mochi Health) is $50/month more for what is essentially the same medication from a similar compounding pharmacy — that's $600/year of savings for the same molecule.
Beyond price, MEDVi gets the operational basics right: cold-chain shipping arrives reliably within 2–4 days, the medication is properly labeled with concentration and beyond-use date, the provider network is real (US-licensed physicians and NPs), and the cancellation policy is straightforward.
Mochi Health is the strongest runner-up to MEDVi. It costs $50/month more for the base tirzepatide subscription, but adds optional coaching and B12 add-ons that some patients value. The provider experience is well-regarded, and the company has built a solid reputation in the GLP-1 telehealth space since 2022.
Best for: patients who want coaching support included or who value the optional B12/pyridoxine bundles for fatigue and nausea management.
Henry Meds was one of the first compounded GLP-1 telehealth providers and has built a reputation for transparent pricing and reliable service. At $269/month it's pricier than MEDVi but still well below the $300+ tier. The platform is straightforward without too many add-on upsells.
Best for: patients who prefer a long-established provider with a straightforward, no-frills experience.
Eden offers compounded tirzepatide at $296/month with provider messaging and flexible subscription terms. The pricing is in the middle tier and the user experience is solid. Not the cheapest but offers good provider responsiveness.
Hers (the women-focused arm of Hims & Hers) offers compounded tirzepatide at $299/month — roughly 50% more than MEDVi for what is essentially the same molecule from a similar compounding pharmacy. The premium buys brand recognition, a polished mobile app, and a more curated experience. For cash-pay patients optimizing for cost-effectiveness, MEDVi delivers more value.
Best for: patients who value brand recognition, mobile-first user experience, and don't mind paying $1,200/year more than the lowest legitimate option.
Ro is a major venture-funded telehealth brand offering tirzepatide at the upper end of the price range. The user experience is polished and the platform includes optional concierge services. The price premium vs MEDVi is substantial — $130/month, or $1,560/year — for largely non-clinical features.
Brello sits at the higher end of the price spectrum at $349/month. The platform offers a competent telehealth experience but the premium over MEDVi is substantial without proportional clinical advantages.
| Rank | Provider | Starting price | Verdict |
|---|---|---|---|
| #1 | MEDVi | $199/mo | Editor's Choice — cheapest legitimate |
| #2 | Mochi Health | $249/mo | Strong runner-up with coaching options |
| #3 | Henry Meds | $269/mo | Long-established, transparent |
| #4 | Eden | $296/mo | Solid mid-tier |
| #5 | Hers | $299/mo | Brand premium for similar product |
| #6 | Ro | $329/mo | Premium tier with concierge features |
| #7 | Brello | $349/mo | Higher tier |
MEDVi consistently delivers the lowest US-licensed cash-pay tirzepatide pricing in 2026. Editor's Choice. Same molecule as the more expensive providers.
Start With MEDVi→For 2026, our Editor's Choice is MEDVi — the combination of the lowest published self-pay price ($199/month), US-licensed providers, transparent pricing, and reliable cold-chain shipping makes it the strongest cash-pay value. Mochi Health, Henry Meds, and Eden are strong runners-up if MEDVi is unavailable in your state.
MEDVi has been operating since 2022 and has accumulated thousands of patient reviews across third-party platforms (Trustpilot, Reddit, BBB). Aggregate ratings are positive, with the most common positive themes being price, fast approval, and friendly customer service. Negative reviews tend to focus on shipping delays during high-demand periods and the fact that MEDVi is not available in every US state.
Hers offers tirzepatide at $299/month — about 50% more than MEDVi for what is essentially the same molecule from a similar compounding pharmacy. The premium buys: a polished mobile app, a recognizable brand, and a slightly more curated user experience. For most cash-pay patients, the math doesn't favor Hers over MEDVi unless you specifically value those non-clinical features.
Mochi Health offers compounded tirzepatide at $249/month and is consistently well-reviewed for provider responsiveness, coaching add-ons, and dose flexibility. It's our #2 pick for 2026. The main downsides: prices on the higher tirzepatide doses (12.5 and 15 mg) can climb above $300/month, and the coaching add-ons are upsells that not everyone needs.
Ro is a major telehealth brand with substantial venture funding and a polished product. Tirzepatide pricing starts at $329/month, with optional concierge and add-on services. Reviews are generally positive but the price premium vs MEDVi or Mochi is substantial. Ro is a reasonable choice if you value brand recognition or want bundled wellness features.
Not always — but in 2026, MEDVi is both. Cheapest doesn't equal sketchy: MEDVi keeps prices low through scale, direct compounding pharmacy partnerships, and minimal add-on service overhead. Other low-price tirzepatide offers (under $150/month) are usually warning signs of gray-market sourcing or operational corner-cutting. MEDVi's $199 price point is sustainable and legitimate.
Step-by-step process from sign-up to first injection.
Sortable table of every provider's price by dose.
What it is, why it's cheaper, regulatory status.